Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
- 1 March 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 111 (5) , 2785-2789
- https://doi.org/10.1182/blood-2007-06-095703
Abstract
JAK2V617F is an acquired mutation associated with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). We tested the hypothesis that the paradox of a single disease allele associated with 3 distinctive clinical phenotypes could be explained in part by host-modifying influences. We screened for genetic variation within 4 candidate genes involved in JAK-STAT signaling, including receptors for erythropoietin (EPOR), thrombopoietin (MPL), and granulocyte colony-stimulating factor (GCSFR), and JAK2. We genotyped 32 linkage disequilibrium tag single nucleotide polymorphism (SNP) loci in 179 white patients: 84 had PV, 58 had PMF, and 37 had ET. Genotype-phenotype analysis showed 3 JAK2 SNPs (rs7046736, rs10815148, and rs12342421) to be significantly but reciprocally associated with PV (P < .001 for all; odds ratio = 0.16, 2.72, and 2.46, respectively) and ET (P < .001 for all; odds ratio = 3.05, 0.29, and 0.30, respectively) but not with PMF. Three additional JAK2 SNPs (rs10758669, rs3808850, and rs10974947) and a single EPOR SNP (rs318699) were also significantly associated with PV but not with ET or PMF. Finally, intragene haplotypes in JAK2 were significantly associated with PV only. Thus, host genetic variation may contribute to phenotypic diversity among myeloproliferative disorders, including in the presence of a shared disease allele.Keywords
This publication has 22 references indexed in Scilit:
- Extending Jak2V617F and MplW515 Mutation Analysis to Single Hematopoietic Colonies and B and T LymphocytesThe International Journal of Cell Cloning, 2007
- Oncogenes in Myeloproliferative DisordersCell Cycle, 2007
- Polycythemia vera is not initiated by JAK2 mutationExperimental Hematology, 2007
- Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disordersBlood, 2006
- Expression of Jak2V617F causes a polycythemia vera–like disease with associated myelofibrosis in a murine bone marrow transplant modelBlood, 2006
- Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disordersBlood, 2006
- X-inactivation–based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesisBlood, 2006
- Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disordersLeukemia, 2006
- JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemiaBlood, 2005
- Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesisCell, 1998